SciClone Pharmaceuticals announced that Zadaxin, a hepatitis C treatment, failed to meet its primary endpoint in the first of two Phase III trials. The study found that treatment with Zadaxin and pegylated interferon alpha did not demonstrate a statistically significant benefit compared to treatment with pegylated interferon alone in sustained viral response (SVR) or histologic improvement, the trial's co-primary endpoints. SciClone's shares dropped sharply upon the news.
- read SciClone's press release